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syndrome (ACS) patients irrespective of stent length.
METHODS PROMETHEUS was a retrospective multicenter observa-
tional study comparing clopidogrel and prasugrel use in patients un-
dergoing PCI for acute coronary syndrome. MACE was deﬁned as a
composite of death, myocardial infarction, stroke and unplanned
revascularization at one year. We compared outcomes between clo-
pidogrel and prasugrel treatment stratiﬁed by stent length < or 40
mm.
RESULTS Prasugrel was given to 20.0% and 22.0% of patients
receiving short (n¼14790) and long stents (n¼4695) respectively.
Compared with clopidogrel treated patients, those receiving prasugrel
were younger, more often male, with lower frequencies of diabetes,
prior PCI, renal dysfunction and anemia but higher left ventricular
ejection fraction. The incidence of STEMI presentation, B2/C type
lesions, single vessel and non-signiﬁcantly calciﬁed disease was
higher in prasugrel treated patients with a greater likelihood to
receive drug eluting stents and stents >2.5mm in diameter. The
overall crude MACE rate for the study population was 12.1% vs 20.7%
with prasugrel compared with clopidogrel, p<0.001. In the short-
stent group prasugrel was associated with a signiﬁcantly lower risk
for MACE prior to adjustment (10.7% vs. 18.6%, p<0.001). Analogous
event rates in the long-stent group were 15.8% and 26.7%, respec-
tively (p<0.001). Results remained signiﬁcant for short but not long
stents after adjustment without evidence of interaction (p¼0.98)
(Figure).
CONCLUSIONS Compared with clopidogrel, prasugrel use afforded
ischemic beneﬁt irrespective of stent length in real-world ACS pa-
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United StatesBACKGROUND Despite pharmacological advantages, prasugrel may
be preferentially used in patients with higher body-mass index (BMI)
in the real-world due to concerns regarding bleeding. We sought to
examine the frequency of prasugrel use in patients with lower (<30)
and higher (30) BMI, and to compare the MACE rate in these sub-
groups for patients treated with prasugrel versus clopidogrel.
METHODS PROMETHEUS was a retrospective multicenter observa-
tional study comparing clopidogrel and prasugrel use in patients un-
dergoing PCI for acute coronary syndrome. MACE was deﬁned as a
composite of death, myocardial infarction, stroke and unplanned
revascularization at one year. We compared outcomes between clo-
pidogrel and prasugrel treatment stratiﬁed by BMI.
RESULTS Prasugrel was given to 19.0% and 22.0% of patients with
BMI<30 (n¼10678) and BMI30 (n¼9184) respectively. Compared
with clopidogrel, prasugrel treated patients were younger, male, with
less diabetes or prior PCI but greater incidence of smoking at baseline
and a STEMI/NSTEMI presentation. They had a greater incidence of
B2/C type lesions but single vessel and non-signiﬁcantly calciﬁed
disease with a greater likelihood to receive longer stents and stents
>3.0mm in diameter. The overall crude MACE rate for the study
population was 12.1% vs 20.7% with prasugrel compared with clopi-
dogrel, p<0.001. In the BMI<30 group prasugrel was associated with a
signiﬁcantly lower risk for MACE prior to adjustment (12.7% vs. 21.3%,
p<0.001). Analogous event rates in the BMI30 group were 11.5% and
19.9%, respectively (p<0.001). Results remained signiﬁcant for
BMI30 but not BMI<30 without evidence of interaction after
adjustment (p¼0.98) (Figure).
CONCLUSIONS In a real world setting, the use of prasugrel was
similar in patients with BMI < and 30. Compared with clopidogrel,
prasugrel use afforded ischemic beneﬁt irrespective of BMI in real-
world ACS patients undergoing PCI.
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